生物感测器市场机会、成长动力、产业趋势分析与预测 2024 - 2032

全球生物感测器市场估值于2023 年达到301 亿美元，预计2024 年至2032 年复合年增长率为7.7%。解决方案的需求不断增加。市场分为可穿戴式和非穿戴式生物感测器。由于整合到用于即时 (POC) 测试的诊断设备中，非可穿戴生物感测器在 2023 年占据了 64.2% 的巨大份额。这些生物感测器具有多种优点，包括易于使用、高精度以及无需用户持续输入即可快速提供诊断结果的能力。

在 POC 设定中，非穿戴式生物感测器对于快速测试和诊断非常有价值，可以加快治疗决策并改善患者治疗效果。感测器技术的进步，例如增强的灵敏度、小型化以及与数位平台的兼容性，进一步增强了它们的功能和吸引力。从技术上讲，生物感测器市场分为电化学、光学、热学、压电和其他类别。电化学生物感测器因其高灵敏度、特异性和快速反应时间而在 2023 年以 125 亿美元的收入引领市场，使其成为医疗应用的理想选择。

这些生物感测器是血糖仪等设备的核心，糖尿病患者广泛使用这些设备来监测血糖水平。生物感测器市场也按最终用途细分，涵盖现场检测、家庭医疗诊断、研究实验室和其他领域。到 2032 年，即时检测 (POC) 领域预计将达到 298 亿美元。这种迅速反应对于管理紧急情况和紧急情况、减少等待时间以及促进即时临床干预至关重要。

这种效率对于紧急护理和慢性病管理尤其有益。从地区来看，美国在北美生物感测器市场占据主导地位，到 2023 年将产生 95 亿美元的收入，预计在预测期内将大幅成长。美国的高额医疗支出和有利的保险政策鼓励对先进生物感测器技术的投资，提高患者的可及性和负担能力。总而言之，在医疗诊断和护理点应用对高效医疗保健解决方案的需求的推动下，生物感测器市场正处于强劲的成长轨道。的增长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 生物感测器在医学领域的应用日益广泛
    • 全球糖尿病盛行率上升
    • 亚太地区和欧洲对便携式生物感测器的高需求
    • 技术进步
  • 产业陷阱与挑战
    • 严格的监管场景
    • 产品开发成本高
• 成长潜力分析
• 监管环境
  • 我们
  • 欧洲
• 技术景观
  • 当前产业趋势
  • 启动场景
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略展望矩阵

第 5 章：市场估计与预测：按类型，2021 - 2032

• 主要趋势
• 穿戴式生物感测器
• 非穿戴式生物感测器

第 6 章：市场估计与预测：按技术划分，2021 - 2032 年

• 主要趋势
• 电化学
• 光学的
• 热的
• 压电式
• 其他技术

第 7 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 血糖检测
• 胆固醇测试
• 血气分析
• 妊娠检测
• 药物发现
• 传染病检测
• 其他应用

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 护理点测试
• 家庭医疗保健诊断
• 研究实验室
• 其他最终用户

第 9 章：市场估计与预测：按地区划分，2021 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 俄罗斯
  • 瑞士
• 亚太地区
  • 中国
  • 日本
  • 印度
• 拉丁美洲
  • 巴西
  • 墨西哥
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯

第 10 章：公司简介

• Abbott Laboratories
• Ascensia Diabetes Care Holdings
• Bio-Rad Laboratories
• Biosensors International Group
• Danaher Corporation
• Dexcom
• F. Hoffmann-La Roche
• LifeScan
• Masimo
• Nova Biomedical
• Pinnacle Technology
• QTL Biosystems
• Siemens Healthineers
• TE Connectivity Corporation
• Thermo Fisher Scientific

The Global Biosensors Market reached a valuation of USD 30.1 billion in 2023 and is anticipated to grow at a 7.7% CAGR from 2024 to 2032. The primary driver behind this growth is the rising global prevalence of diabetes and increasing demand for efficient monitoring and diagnostic solutions. The market is divided into wearable and non-wearable biosensors. Non-wearable biosensors held a substantial 64.2% share in 2023, thanks to their integration into diagnostic devices used for point-of-care (POC) testing. These biosensors provide several benefits, including ease of use, high accuracy, and the ability to deliver quick diagnostic results without continuous user input.

In POC settings, non-wearable biosensors are invaluable for rapid testing and diagnosis, leading to faster treatment decisions and improved patient outcomes. Advances in sensor technology, such as enhanced sensitivity, miniaturization, and compatibility with digital platforms, further boost their functionality and appeal. Technologically, the biosensors market is segmented into electrochemical, optical, thermal, piezoelectric, and other categories. Electrochemical biosensors led the market with USD 12.5 billion in revenue in 2023, driven by their high sensitivity, specificity, and quick response times, making them ideal for medical applications.

These biosensors are central to devices like glucose meters, widely used by diabetic patients to monitor blood sugar levels. The biosensors market is also segmented by end-use, covering point-of-care testing, home healthcare diagnostics, research labs, and other sectors. The point-of-care testing (POC) segment is expected to reach USD 29.8 billion by 2032. Biosensors are key to POC testing, offering rapid results that enable quick diagnosis and decision-making. This prompt response is crucial in managing acute conditions and emergencies, reducing waiting times, and facilitating immediate clinical interventions.

Such efficiency is especially beneficial in emergency care and chronic disease management. Regionally, the U.S. dominated the North American biosensors market, generating USD 9.5 billion in revenue in 2023, with substantial growth expected over the forecast period. High healthcare expenditure and favorable insurance policies in the U.S. encourage investment in advanced biosensor technologies, enhancing accessibility and affordability for patients. In summary, the biosensors market is on a strong growth trajectory, driven by the demand for efficient healthcare solutions across medical diagnostics and point-of-care applications.Innovations in technology and favorable conditions in key regions like the U.S. are expected to further propel market growth through 2032.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing application of biosensors in medical field
    • 3.2.1.2 Rising prevalence of diabetes globally
    • 3.2.1.3 High demand for portable biosensors in Asia Pacific and Europe
    • 3.2.1.4 Technological advancements
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory scenario
    • 3.2.2.2 High cost of product development
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 U.S.
  • 3.4.2 Europe
• 3.5 Technological landscape
  • 3.5.1 Current trends in the industry
  • 3.5.2 Start-up scenario
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Wearable biosensors
• 5.3 Non-wearable biosensors

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Electrochemical
• 6.3 Optical
• 6.4 Thermal
• 6.5 Piezoelectric
• 6.6 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Blood glucose testing
• 7.3 Cholesterol testing
• 7.4 Blood gas analysis
• 7.5 Pregnancy testing
• 7.6 Drug discovery
• 7.7 Infectious disease testing
• 7.8 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Point of care testing
• 8.3 Home healthcare diagnostics
• 8.4 Research laboratories
• 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Russia
  • 9.3.7 Switzerland
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 Ascensia Diabetes Care Holdings
• 10.3 Bio-Rad Laboratories
• 10.4 Biosensors International Group
• 10.5 Danaher Corporation
• 10.6 Dexcom
• 10.7 F. Hoffmann-La Roche
• 10.8 LifeScan
• 10.9 Masimo
• 10.10 Nova Biomedical
• 10.11 Pinnacle Technology
• 10.12 QTL Biosystems
• 10.13 Siemens Healthineers
• 10.14 TE Connectivity Corporation
• 10.15 Thermo Fisher Scientific